Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 … – PR Newswire (press release)

by admin on July 30, 2013

Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7
PR Newswire (press release)
Convergence Pharmaceuticals Limited ("Convergence" or "the company"), the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, is pleased to announce that its novel sodium channel blocker, 

and more »

View full post on chronic pain – Google News

Previous post:

Next post: